Baxter International Q1 Revenue Rises 2.9% to $2.70B, EPS Beats
Baxter International reported Q1 revenue of $2.70 billion, up 2.9% year-on-year and surpassing the $2.62 billion consensus. Its EPS of $0.36 topped estimates by over 15%, while debt-to-equity stood at 1.60 and the current ratio reached 2.31, indicating solid liquidity.
1. First-Quarter Revenue Performance
Baxter delivered Q1 revenue of $2.70 billion, up 2.9% year-over-year, exceeding the $2.62 billion consensus and reflecting stronger sales across key medical product lines.
2. EPS and Profitability
Q1 EPS reached $0.36, surpassing the $0.31 estimate by more than 15% despite a drop from $0.55 a year ago, signaling cost management and pricing effectiveness.
3. Financial Health Metrics
The company’s debt-to-equity ratio stands at 1.60, while the current ratio of 2.31 underscores ample liquidity to meet short-term obligations and maintain operational flexibility.